Li Y, Fang Y, Chen X, Tong L, Feng F, Zhou Q
Acta Pharm Sin B. 2025; 15(1):438-466.
PMID: 40041917
PMC: 11873650.
DOI: 10.1016/j.apsb.2024.10.002.
Zhang X, Zhang M, Li Y, Deng P
Curr Issues Mol Biol. 2025; 47(1.
PMID: 39852144
PMC: 11764389.
DOI: 10.3390/cimb47010029.
Wang Y, Minden A
Int J Mol Sci. 2024; 25(18).
PMID: 39337621
PMC: 11431865.
DOI: 10.3390/ijms251810138.
Ismail M, Shawer T, Ibrahim R, Abusaif M, Kamal M, Allam R
RSC Adv. 2023; 13(45):31908-31924.
PMID: 37915441
PMC: 10616755.
DOI: 10.1039/d3ra05066a.
Li Y, Lu Q, Xie C, Yu Y, Zhang A
Front Pharmacol. 2022; 13:956220.
PMID: 36105226
PMC: 9465411.
DOI: 10.3389/fphar.2022.956220.
Targeting p21-activated kinase 4 (PAK4) with pyrazolo[3,4-]pyrimidine derivative SPA7012 attenuates hepatic ischaemia-reperfusion injury in mice.
Mao Y, Lee E, Yang X, Bae E, Jeon R, Park B
J Enzyme Inhib Med Chem. 2022; 37(1):2133-2146.
PMID: 35920284
PMC: 9354638.
DOI: 10.1080/14756366.2022.2106478.
Recent progress on vascular endothelial growth factor receptor inhibitors with dual targeting capabilities for tumor therapy.
Liu Y, Li Y, Wang Y, Lin C, Zhang D, Chen J
J Hematol Oncol. 2022; 15(1):89.
PMID: 35799213
PMC: 9263050.
DOI: 10.1186/s13045-022-01310-7.
Synthesis of selective PAK4 inhibitors for lung metastasis of lung cancer and melanoma cells.
Song P, Zhao F, Li D, Qu J, Yao M, Su Y
Acta Pharm Sin B. 2022; 12(6):2905-2922.
PMID: 35755272
PMC: 9214071.
DOI: 10.1016/j.apsb.2022.02.029.
Structure Based Design of Potent Selective Inhibitors of Protein Kinase D1 (PKD1).
Feng J, Lee P, Alaoui M, Barrett K, Castanedo G, Godemann R
ACS Med Chem Lett. 2019; 10(9):1260-1265.
PMID: 31531194
PMC: 6746091.
DOI: 10.1021/acsmedchemlett.8b00658.
Targeting Dynamic ATP-Binding Site Features Allows Discrimination between Highly Homologous Protein Kinases.
Chakraborty S, Inukai T, Fang L, Golkowski M, Maly D
ACS Chem Biol. 2019; 14(6):1249-1259.
PMID: 31038916
PMC: 6642640.
DOI: 10.1021/acschembio.9b00214.
PAK4 crystal structures suggest unusual kinase conformational movements.
Zhang E, Ha B, Boggon T
Biochim Biophys Acta Proteins Proteom. 2017; 1866(2):356-365.
PMID: 28993291
PMC: 5742302.
DOI: 10.1016/j.bbapap.2017.10.004.
A novel orally bioavailable compound KPT-9274 inhibits PAK4, and blocks triple negative breast cancer tumor growth.
Rane C, Senapedis W, Baloglu E, Landesman Y, Crochiere M, Das-Gupta S
Sci Rep. 2017; 7:42555.
PMID: 28198380
PMC: 5309789.
DOI: 10.1038/srep42555.
Discovery of a Chemical Probe Bisamide (CCT251236): An Orally Bioavailable Efficacious Pirin Ligand from a Heat Shock Transcription Factor 1 (HSF1) Phenotypic Screen.
Cheeseman M, Chessum N, Rye C, Pasqua A, Tucker M, Wilding B
J Med Chem. 2016; 60(1):180-201.
PMID: 28004573
PMC: 6014687.
DOI: 10.1021/acs.jmedchem.6b01055.
Identifying three-dimensional structures of autophosphorylation complexes in crystals of protein kinases.
Xu Q, Malecka K, Fink L, Jordan E, Duffy E, Kolander S
Sci Signal. 2015; 8(405):rs13.
PMID: 26628682
PMC: 4766099.
DOI: 10.1126/scisignal.aaa6711.
An in cellulo-derived structure of PAK4 in complex with its inhibitor Inka1.
Baskaran Y, Ang K, Anekal P, Chan W, Grimes J, Manser E
Nat Commun. 2015; 6:8681.
PMID: 26607847
PMC: 4674680.
DOI: 10.1038/ncomms9681.
p21-activated kinase group II small compound inhibitor GNE-2861 perturbs estrogen receptor alpha signaling and restores tamoxifen-sensitivity in breast cancer cells.
Zhuang T, Zhu J, Li Z, Lorent J, Zhao C, Dahlman-Wright K
Oncotarget. 2015; 6(41):43853-68.
PMID: 26554417
PMC: 4791272.
DOI: 10.18632/oncotarget.6081.
Optimization of a Dibenzodiazepine Hit to a Potent and Selective Allosteric PAK1 Inhibitor.
Karpov A, Amiri P, Bellamacina C, Bellance M, Breitenstein W, Daniel D
ACS Med Chem Lett. 2015; 6(7):776-81.
PMID: 26191365
PMC: 4499825.
DOI: 10.1021/acsmedchemlett.5b00102.
Leveraging the Pre-DFG Residue Thr-406 To Obtain High Kinase Selectivity in an Aminopyrazole-Type PAK1 Inhibitor Series.
Rudolph J, Aliagas I, Crawford J, Mathieu S, Lee W, Chao Q
ACS Med Chem Lett. 2015; 6(6):711-5.
PMID: 26101579
PMC: 4468403.
DOI: 10.1021/acsmedchemlett.5b00151.
Targeting cancer with kinase inhibitors.
Gross S, Rahal R, Stransky N, Lengauer C, Hoeflich K
J Clin Invest. 2015; 125(5):1780-9.
PMID: 25932675
PMC: 4463189.
DOI: 10.1172/JCI76094.
Signaling, Regulation, and Specificity of the Type II p21-activated Kinases.
Ha B, Morse E, Turk B, Boggon T
J Biol Chem. 2015; 290(21):12975-83.
PMID: 25855792
PMC: 4505552.
DOI: 10.1074/jbc.R115.650416.